Literature DB >> 22915266

Overexpression of SASH1 related to the decreased invasion ability of human glioma U251 cells.

Liu Yang1, Mei Liu, Zhikai Gu, Jianguo Chen, Yaohua Yan, Jian Li.   

Abstract

The purpose of this study was to investigate the impact of SAM- and SH3-domain containing 1 (SASH1) on the biological behavior of glioma cells, including its effects on cellular growth, proliferation, apoptosis, invasion, and metastasis, and thereby to provide an experimental basis for future therapeutic treatments. A pcDNA3.1-SASH1 eukaryotic expression vector was constructed and transfected into the U251 human glioma cell line. Using the tetrazolium-based colorimetric (MTT) assay, flow cytometry analyses, transwell invasion chamber experiments, and other methods, we examined the impact of SASH1 on the biological behaviors of U251 cells, including effects on viability, cell cycle, apoptosis, and invasion. Furthermore, the effect of SASH1 on the expression of cyclin D1, caspase-3, matrix metalloproteinase (MMP)-2, MMP-9, and other proteins was observed. Compared to the empty vector and blank control groups, the pcDNA3.1-SASH1 group of U251 cells exhibited significantly reduced cell viability, proliferation, and invasion (p < 0.05), although there was no difference between the empty vector and blank control groups. The pcDNA3.1-SASH1 group demonstrated a significantly higher apoptotic index than did the empty vector and blank control groups (p < 0.05), and the percentage of apoptotic cells was similar between the empty vector and blank control groups. In addition, the pcDNA3.1-SASH1 group expressed significantly lower protein levels of cyclin D1 and MMP-2/9 compared to the control and empty vector groups (p < 0.05) and significantly higher protein levels of caspase-3 than the other two groups (p < 0.05). Cyclin D1, caspase-3, and MMP-2/9 expression was unchanged between the empty vector and blank control groups. SASH1 gene expression might be related to the inhibition of the growth, proliferation, and invasion of U251 cells and the promotion of U251 cells apoptosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22915266     DOI: 10.1007/s13277-012-0487-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  39 in total

Review 1.  Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.

Authors:  Marc C Chamberlain
Journal:  Expert Rev Neurother       Date:  2010-10       Impact factor: 4.618

Review 2.  UV-radiation, apoptosis and skin.

Authors:  Nives Pustisek; Mirna Situm
Journal:  Coll Antropol       Date:  2011-09

3.  Epigallocatechin-3-gallate (EGCG) downregulates EGF-induced MMP-9 in breast cancer cells: involvement of integrin receptor α5β1 in the process.

Authors:  Triparna Sen; Amitava Chatterjee
Journal:  Eur J Nutr       Date:  2010-12-19       Impact factor: 5.614

4.  Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors.

Authors:  A Barghorn; E J Speel; B Farspour; P Saremaslani; S Schmid; A Perren; J Roth; P U Heitz; P Komminoth
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

5.  The unliganded glucocorticoid receptor positively regulates the tumor suppressor gene BRCA1 through GABP beta.

Authors:  Heather D Ritter; Lilia Antonova; Christopher R Mueller
Journal:  Mol Cancer Res       Date:  2012-02-10       Impact factor: 5.852

6.  Molecular genetic and epigenetic analysis of NCX2/SLC8A2 at 19q13.3 in human gliomas.

Authors:  M Qu; H Jiao; J Zhao; Z-P Ren; A Smits; J Kere; M Nistér
Journal:  Neuropathol Appl Neurobiol       Date:  2010-02-26       Impact factor: 8.090

7.  Normal tissue protection for improving radiotherapy: Where are the Gaps?

Authors:  Pataje G S Prasanna; Helen B Stone; Rosemary S Wong; Jacek Capala; Eric J Bernhard; Bhadrasain Vikram; C N Coleman
Journal:  Transl Cancer Res       Date:  2012-06       Impact factor: 1.241

8.  Children's Oncology Group L991 final study report: Establishing an important benchmark for assessing late effects of trimodality care of pediatric patients treated for high grade gliomas.

Authors:  Ralph Ermoian; Matthew Ladra; Shilpen Patel
Journal:  Transl Pediatr       Date:  2012-07

9.  EMMPRIN contributes to the in vitro invasion of human salivary adenoid cystic carcinoma cells.

Authors:  Xinjie Yang; Pu Zhang; Qin Ma; Liang Kong; Yuan Li; Baolin Liu; Delin Lei
Journal:  Oncol Rep       Date:  2011-12-22       Impact factor: 3.906

10.  Essential role of protein kinase C zeta in transducing a motility signal induced by superoxide and a chemotactic peptide, fMLP.

Authors:  Kageaki Kuribayashi; Kiminori Nakamura; Maki Tanaka; Tsutomu Sato; Junji Kato; Katsunori Sasaki; Rishu Takimoto; Katsuhisa Kogawa; Takeshi Terui; Tetsuji Takayama; Takayuki Onuma; Takuya Matsunaga; Yoshiro Niitsu
Journal:  J Cell Biol       Date:  2007-03-26       Impact factor: 10.539

View more
  20 in total

1.  SASH1 inhibits proliferation and invasion of thyroid cancer cells through PI3K/Akt signaling pathway.

Authors:  Dawei Sun; Rui Zhou; Huamin Liu; Wenhai Sun; Anbing Dong; Hongmei Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.

Authors:  Xi Chen; Yixiao Yuan; Wenjun Ren; Fan Zhou; Xiaobin Huang; Jun Pu; Xiaoqun Niu; Xiulin Jiang
Journal:  Front Oncol       Date:  2022-06-03       Impact factor: 5.738

3.  Autosomal-recessive SASH1 variants associated with a new genodermatosis with pigmentation defects, palmoplantar keratoderma and skin carcinoma.

Authors:  Jean-Benoît Courcet; Siham Chafai Elalaoui; Laurence Duplomb; Mariam Tajir; Jean-Baptiste Rivière; Julien Thevenon; Nadège Gigot; Nathalie Marle; Bernard Aral; Yannis Duffourd; Alain Sarasin; Valeria Naim; Emilie Courcet-Degrolard; Marie-Hélène Aubriot-Lorton; Laurent Martin; Jamal Eddin Abrid; Christel Thauvin; Abdelaziz Sefiani; Pierre Vabres; Laurence Faivre
Journal:  Eur J Hum Genet       Date:  2014-10-15       Impact factor: 4.246

4.  Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma.

Authors:  Xiaoyan Ren; Yifei Liu; Yumei Tao; Guoxiang Zhu; Meilan Pei; Jianguo Zhang; Jian Liu
Journal:  Oncol Lett       Date:  2016-03-17       Impact factor: 2.967

5.  CARMA3 is overexpressed in human glioma and promotes cell invasion through MMP9 regulation in A172 cell line.

Authors:  Xingjun Feng; Guozhuan Miao; Yipeng Han; Yi Xu
Journal:  Tumour Biol       Date:  2013-07-27

Review 6.  Systematic review of protein biomarkers of invasive behavior in glioblastoma.

Authors:  Eli T Sayegh; Gurvinder Kaur; Orin Bloch; Andrew T Parsa
Journal:  Mol Neurobiol       Date:  2013-11-24       Impact factor: 5.590

7.  Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts.

Authors:  Joshua C Doloff; David J Waxman
Journal:  BMC Cancer       Date:  2015-05-08       Impact factor: 4.430

8.  Clinical Significance of SASH1 Expression in Glioma.

Authors:  Liu Yang; Haitao Zhang; Qi Yao; Yingying Yan; Ronghua Wu; Mei Liu
Journal:  Dis Markers       Date:  2015-09-06       Impact factor: 3.434

9.  SASH1 Is Involved in an Autosomal Dominant Lentiginous Phenotype.

Authors:  Yiqun G Shellman; Karoline A Lambert; Anne Brauweiler; Pamela Fain; Richard A Spritz; Melanie Martini; Klaus-Peter Janssen; Neil F Box; Tamara Terzian; Marian Rewers; Anelia Horvath; Constantine A Stratakis; William A Robinson; Steven E Robinson; David A Norris; Kristin B Artinger; Theresa R Pacheco
Journal:  J Invest Dermatol       Date:  2015-07-23       Impact factor: 8.551

10.  SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer.

Authors:  Joshua T Burgess; Emma Bolderson; Jodi M Saunus; Shu-Dong Zhang; Lynne E Reid; Anne Marie McNicol; Sunil R Lakhani; Katharine Cuff; Kerry Richard; Derek J Richard; Kenneth J O'Byrne
Journal:  Oncotarget       Date:  2016-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.